Risk factors with no estimates of population attributable fraction
Risk factors for colorectal cancer with population attributable fractions less than 1% or which have not been
calculated are described below.
Colorectal cancer due to aging
Advancing age is an important risk factor for colorectal cancer; 78% of cases are diagnosed at age 55 years and
older, and 15% occur at ages 45 to 54 years (Colorectal Cancer Screening (PDQ®) Health Professional Version,
accessed 29May20). The median age at diagnosis is 68 years (NIH > NCI > Age, accessed 29May20). However, the
population attributable fraction for aging has not been determined.
Aging acts in several ways to promote carcinogenesis. First, aging is associated with DNA methylation in normal
colonic tissue, particularly in patients at high risk (Wang 2020), that progresses to hypermethylation in colorectal
cancer (Ahuja 1998). These changes lower the threshold for malignant transformation (Nakagawa 2001, Xu 2014),
perhaps by altering chromatin conformation and stability (Lin 2015). They may also affect the mRNA expression of
adenoma and colorectal cancer related control genes (Galamb 2016).
Second, aging provides more time for chronic stressors to exert their effects (Martincorena 2015), which may take
decades. In addition, longer lifetimes allow for more interactions between the networks which they alter.
Third, aging is associated with immune system dysfunction, a known chronic stressor which causes malignancy
(Zhang 2016, Sadighi 2018). It may also affect the microenvironment (Marongiu 2016).
The rate of aging is controlled in part by nutrient sensing pathways (insulin or IGF1 signaling, mTOR, AMPK and
sirtuins) that have been evolutionary conserved from worms to humans (Yokoyama 2015). These pathways are also
commonly involved in carcinogenesis and cancer metabolism. Metformin, resveratrol, Rhodiola and other agents that
target these pathways may have both anti-aging and preventative, anti-colon cancer efficacy (Nguyen 2009,
McCubrey 2017)
Colorectal cancer due to type II diabetes
Type II diabetes is associated with a mildly elevated relative risk (1.2 to 1.4) of colorectal cancer (Tsilidis 2015, Lin
2014), particularly in men (Ma 2018), although a population attributable fraction risk has not been calculated. It is
unclear whether this association is due to shared risk factors (excess weight, diet, physical inactivity, aging) or due to
metabolic derangements of diabetes (hyperglycemia, insulin resistance, hyperinsulinemia, Giovannucci 2010) and
alterations of the insulin-like growth factor system (Scappaticcio 2017, Pollak 2004), which may create a low grade
chronic inflammatory state (Gristina 2015) and otherwise drive cancer metabolic reprogramming (Tudzarova 2015).
Colorectal cancer due to inflammatory bowel disease
Patients with longstanding ulcerative colitis and Crohn disease may have an increased risk of colorectal cancer which
increases with the duration and extent of colitis, degree of inflammation, the presence of primary sclerosing
cholangitis and family history of colorectal cancer (Triantafillidis 2009, Laukoetter 2011). No population attributable
fraction has been calculated. However, the incidence has been decreasing in western countries (Kim 2014) and there
is substantial heterogeneity between studies; some authors question whether there actually is an increased risk
(Wheat 2016, Adami 2016).
Although the pathogenesis of colorectal cancer in these patients is poorly understood, there are several suggested
mechanisms. First, genetic changes and genomic instability in inflammatory bowel disease and the adenoma-
carcinoma sequence may be similar; in both, histology progresses from no dysplasia to indefinite dysplasia, low
grade dysplasia, high grade dysplasia and finally to invasive adenocarcinoma, although steps can be skipped
(Triantafillidis 2009). Dysplastic lesions tend to be multifocal, in contrast to non-IBD, non-germ line cases, indicating
a field effect (Ullman 2011). These changes may be due to establishment of new hierarchies of molecular patterns,
which may lack associated histologic changes (Pernick 2018c).
Second, host inflammation affects several other risk factors, including the composition and functional capabilities of
gut microbiota (Arthur 2013). In addition, inflammatory mediators TNF, IL17A and IL23 and byproducts such as
reactive oxygen and nitrogen species produce genetic and epigenetic modifications that may lead to carcinogenesis
(Arthur 2013, Däbritz 2014). Hypermethylation of the CpG island silences tumor suppressor genes, including DNA
repair genes such as hMLH1 (Kim 2014).
Colorectal cancer risk reduction due to low dose aspirin
Low dose aspirin is recommended by the US Preventive Services Task Force for the primary prevention of
cardiovascular disease (CVD) and colorectal cancer in adults aged 50 to 59 years who have a 10% or greater 10
year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years and are willing to
take low dose aspirin daily for at least 10 years (US Preventative Services Task Force, accessed 30May20, but see
Chubak 2015). In Australians, daily aspirin use may reduce the incidence of colorectal cancer by 2.3% in men and